DrugDashboards

Bortezomib

Bortezomib · BORTEZOMIB 2.5 mg/1 · Injection, Powder, Lyophilized, For Solution · Intravenous; Subcutaneous · Hospira, Inc.

NDC 00409-1703-01 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE · NDA · View full market →

The short version

22 companies supply this market — deep enough that no single failure threatens the supply.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$1.71per billing unit (0.1 MG)HCPCS J9049 · Jul 1, 2026
  • Part D plans paid (avg)$261.26per dosage unitgross, before rebates — matched by drug name · 2024

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$192.01
Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 0.1 MG
$1.712
HCPCS J9049 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$49,884
320 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $846.17 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA209191
TE code
AP
Approval date
May 2, 2022
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Bortezomib (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
BluePoint LaboratoriesBORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 3, 2026
Eugia US LLCBORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 3, 2026
Apotex CorpBORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Avenacy, LLCBORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
BluePoint LaboratoriesBORTEZOMIB 3.5 mg/3.5mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.BORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Dr.Reddy's Laboratories, Inc.BORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCBORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Gland Pharma LimitedBORTEZOMIB 1 mg/1Jul 15, 2026Sep 2, 2026
Gland Pharma LimitedBORTEZOMIB 2.5 mg/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.BORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Hospira, Inc.BORTEZOMIB 1 mg/1Jul 15, 2026Sep 2, 2026
Hospira, Inc.BORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Hospira, Inc.BORTEZOMIB 2.5 mg/1Jul 15, 2026Sep 2, 2026
Meitheal Pharmaceuticals Inc.BORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Ningbo Shuangcheng Pharmaceutical Co., Ltd.BORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
NorthStar RxLLCBORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Novadoz Pharmaceuticals LLCBORTEZOMIB 3.5 mg/3.5mLJul 15, 2026Sep 2, 2026
Pharmascience Inc.BORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsBORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Sintetica US LLCBORTEZOMIB 3.5 mg/3.5mLJul 15, 2026Sep 2, 2026
Somerset Therapeutics LLCBORTEZOMIB 3.5 mg/3.5mLJul 15, 2026Sep 2, 2026
Takeda Pharmaceuticals America, Inc.BORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Waverley Pharma IncBORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Zydus Lifesciences LimitedBORTEZOMIB 1 mg/mLJul 15, 2026Sep 2, 2026
Zydus Pharmaceuticals USA Inc.BORTEZOMIB 1 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Bortezomib — NDC 00409-1703-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00409170301.

Free to cite with attribution — see how the data is put together.